NCT06693908

A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis

RecruitingPHASE1, PHASE2INTERVENTIONAL

Trial Details

Start: 2025-03-31Est. Completion: 2026-07-09

Enrollment target: 24 participants

Locations

Contact

Reference Study ID Number: GA45735 https://forpatients.roche.com/global-roche-genentech-trials@gene.com 888-662-6728 (U.S.)

Fastest response: use the inquiry form. No email attachments. https://www.gene.com/contact-us/submit-medical-inquiry

Ulcerative Colitis (UC)Inflammatory Bowel Disease (IBD)Colitis

This Phase 2b randomized, double-blind, placebo-controlled, multicenter trial will evaluate the efficacy and safety of a…

Izmir, Turkey (Türkiye)Est. completion May 30, 2027

Ulcerative ColitisInflammatory Bowel DiseasesAutoimmune Diseases

The primary objective of this trial is to evaluate the clinical efficacy of ATH-063 in participants with biologic/advanc…

Miami, United StatesEst. completion Dec 14, 2028

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.